Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 11INDUSTRY 7NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 7Genitourinary 6Endocrine 5CNS 5Head & Neck 3Gynecologic 2Breast 2Plasma cell 1NET 1Lymphoid 1Dermatologic 1

Conditions

Recurrent Uterine Corpus Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × pazopanib × Gynecologic × Clear all
NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 8 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT01468909 2019-07-23

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2 Completed
106 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡